Trial Profile

A phase II Study of Polatuzumab Vedotin (RO5541077) in Combination with Rituximab plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bendamustine (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
Indications Diffuse large B cell lymphoma
Focus Therapeutic Use
Acronyms P-DRIVE
Sponsors Chugai Pharmaceutical

09 Jun 2022 Status changed from active, no longer recruiting to completed.
01 Jul 2021 Results published in the Cancer Science
23 Mar 2021 According to a Chugai Pharmaceutical media release, the Ministry of Health, Labour and Welfare (MHLW) approved Polivy (intravenous infusion 30mg and 140mg) in combination with bendamustine (freeze-dried formulation) and rituximab (BR therapy) for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com